Reactive Arthritis

  • Thomas BardinEmail author


Reactive arthritis (ReA) is a form of spondyloarthropathy which associates with the HLA-B27 antigen and can be defined as a sterile inflammatory arthritis triggered by an infection generally due to a limited number of strict or facultative intracellular pathogens. The two main types of infection are sexually transmitted and intestinal. The clinical course typically includes an oligoarticular arthritis involving large joints of the lower limbs and various extra-articular features, including urethritis, conjunctivitis, and skin or mucosal features. Incomplete forms are frequent, and reactive arthritis may present as an isolated or undifferentiated arthritis. Diagnosis is challenging and relies on the demonstration of the causal infection. Chlamydia, the main cause of sexually acquired reactive arthritis, should be searched by molecular biology techniques in the first morning void of urine. Serology is much less useful for the diagnosis of Chlamydia- or intestinal infection-related reactive arthritis because serological tests lack specificity. The arthritis seems to be related to the presence of infectious components in the involved joints, but the standard bacteriological tests are negative. Clinical course is often prolonged, and the long-term outcome is darkened by frequent relapses and the possibility of development of a chronic arthritis or of ankylosing spondylitis. Poor outcomes are associated with the HLA-B27 carriage, and their frequency varies across the various triggering infections.

There is very little data about the microbiota of reactive arthritis patients.

Management relies on symptomatic medicines, sterilization of the portal of entry in Chlamydia-related arthritis, as well as evaluation for and treatment of other sexually transmittable infections. Long-term treatment by an association of antibiotics has been found helpful in one study of Chlamydia arthritis, whereas no evidence of the benefits of antibiotics has been reported in other types of reactive arthritis. Disease-modifying drugs, such as sulfasalazine or methotrexate, and TNFα blockers are used in chronic reactive arthritis.


Reactive arthritis Spondyloarthritis Microbiota Chlamydia Chlamydia trachomatis Chlamydia pneumoniae Yersinia Salmonella Shigella Campylobacter Antibiotics Spondyloarthropathy HLAB27 



American Rheumatism Association


Deoxyribonucleic acid


Elementary body


Human immunodeficiency virus


Human leucocyte antigen




Interferon gamma


Reticular body


Reactive arthritis


Ribonucleic acid




Sextually transmitted infection


Sexually transmitted reactive arthritis


T helper cell


Tumor necrosis factor


  1. 1.
    Dumonde CD. Introduction to part II: principal evidence associating rheumatic diseases with microbial infection. In: Dumonde CD, editor. Infection and immunology in the rheumatic diseases. Oxford: Blackwell; 1976. p. 95–6.Google Scholar
  2. 2.
    Panush RS, Wallace DJ, Dorff RE, Engleman EP. Retraction of the suggestion to use the term “Reiter’s syndrome” sixty-five years later: the legacy of Reiter, a war criminal, should not be eponymic honor but rather condemnation. Arthritis Rheum. 2007;56(2):693–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Konttinen Y, Nordstrom D, Bergroth V, Leirisalo-Repo M, Santavirta S. Occurrence of different ensuing triggering infections preceding reactive arthritis: a follow up study. Br Med J (Clin Res Ed). 1988;296(6637):1644–5.CrossRefGoogle Scholar
  4. 4.
    Leirisalo-Repo M, Helenius P, Hannu T, Lehtinen A, Kreula J, Taavitsainen M, Koskimies S. Long-term prognosis of reactive salmonella arthritis. Ann Rheum Dis. 1997;56(9):516–20.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gupta NR, Malaviya A, Kaul R, Kumar A, Mehra NK, Shriniwas, Kumar R. Gut flora in HLA-B27 related reactive arthropathy. J Assoc Physicians India. 1986;34(9):634–6.PubMedGoogle Scholar
  6. 6.
    Smith GW, Blackwell CC, Nuki G. Faecal flora in spondyloarthropathy. Br J Rheumatol. 1997;36(8):850–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Manasson J, Shen N, Garcia Ferrer HR, Ubeda C, Iraheta I, Heguy A, Von Feldt JM, Espinoza LR, Garcia Kutzbach A, Segal LN, Ogdie A, Clemente JC, Scher JU. Gut Microbiota Perturbations in Reactive Arthritis and Postinfectious Spondyloarthritis. Arthritis Rheumatol. 2018;70:242–4.CrossRefGoogle Scholar
  8. 8.
    Calin A, Marder A, Marks S, Burns T. Familial aggregation of Reiter’s syndrome and ankylosing spondylitis: a comparative study. J Rheumatol. 1984;11(5):672–7.PubMedGoogle Scholar
  9. 9.
    Yunus M, Calabro JJ, Miller KA, Masi AT. Family studies with HLA typing in Reiter’s syndrome. Am J Med. 1981;70(6):1210–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Adizie T, Moots RJ, Hodkinson B, French N, Adebajo AO. Inflammatory arthritis in HIV positive patients: a practical guide. BMC Infect Dis. 2016;16:100.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Willkens RF, Arnett FC, Bitter T, Calin A, Fisher L, Ford DK, Good AE, Masi AT. Reiter’s syndrome. Evaluation of preliminary criteria for definite disease. Arthritis Rheum. 1981;24(6):844–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Kingsley G, Sieper J. Third international workshop on reactive arthritis. 23-26 September 1995, Berlin, Germany. Report and abstracts. Ann Rheum Dis. 1996;55(8):564–84.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Denison HJ, Curtis EM, Clynes MA, Bromhead C, Dennison EM, Grainger R. The incidence of sexually acquired reactive arthritis: a systematic literature review. Clin Rheumatol. 2016;35(11):2639–48.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Bardin T, Lathrop GM. Postvenereal Reiter’s syndrome in Greenland. Rheum Dis Clin N Am. 1992;18(1):81–93.Google Scholar
  15. 15.
    Zeidler H, Hudson AP. New insights into Chlamydia and arthritis. Promise of a cure? Ann Rheum Dis. 2014;73(4):637–44.CrossRefPubMedGoogle Scholar
  16. 16.
    O’Connell CM, Ferone ME. Chlamydia trachomatis genital infections. Microb Cell. 2016;3(9):390–403.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Gracey E, Inman RD. Chlamydia-induced ReA: immune imbalances and persistent pathogens. Nat Rev Rheumatol. 2011;8(1):55–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Gerard HC, Stanich JA, Whittum-Hudson JA, Schumacher HR, Carter JD, Hudson AP. Patients with Chlamydia-associated arthritis have ocular (trachoma), not genital, serovars of C. Trachomatis in synovial tissue. Microb Pathog. 2010;48(2):62–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Yin Z, Braun J, Neure L, Wu P, Eggens U, Krause A, Kamradt T, Sieper J. T cell cytokine pattern in the joints of patients with Lyme arthritis and its regulation by cytokines and anticytokines. Arthritis Rheum. 1997;40(1):69–79.CrossRefPubMedGoogle Scholar
  20. 20.
    Gerard HC, Stanich JA, Oszust CE, Whittum-Hudson JA, Carter JD, Schumacher HR, Hudson AP. Functional CCR5 receptor protects patients with arthritis from high synovial burden of infecting Chlamydia trachomatis. Am J Med Sci. 2010;340(6):448–51.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Bardin T, Enel C, Cornelis F, Salski C, Jorgensen C, Ward R, Lathrop GM. Antibiotic treatment of venereal disease and Reiter’s syndrome in a Greenland population. Arthritis Rheum. 1992;35(2):190–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Horowitz S, Horowitz J, Taylor-Robinson D, Sukenik S, Apte RN, Bar-David J, Thomas B, Gilroy C. Ureaplasma urealyticum in Reiter’s syndrome. J Rheumatol. 1994;21(5):877–82.PubMedGoogle Scholar
  23. 23.
    Vittecoq O, Schaeverbeke T, Favre S, Daragon A, Biga N, Cambon-Michot C, Bebear C, Le Loet X. Molecular diagnosis of Ureaplasma urealyticum in an immunocompetent patient with destructive reactive polyarthritis. Arthritis Rheum. 1997;40(11):2084–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Fendler C, Laitko S, Sorensen H, Gripenberg-Lerche C, Groh A, Uksila J, Granfors K, Braun J, Sieper J. Frequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis. Ann Rheum Dis. 2001;60(4):337–43.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Reiter H. Uber eine bisher unerkannte Spirochotinfektion (Spirochatosis arthritica). Deutsh Med Wschr. 1916;42:1535–6.CrossRefGoogle Scholar
  26. 26.
    Fiessinger MN, Leroy EM. Contribution à l’étude d’une épidémie de dysenterie dans la Somme (Juillet-Octobre 1916). Bull Soc Med Paris. 1916;40:2030–69.Google Scholar
  27. 27.
    I P. Reiter’s disease: a study of 344 cases observed in Finland. Acta Med Scand. 1948;131(Suppl 2012):1–114.Google Scholar
  28. 28.
    Sairanen E, Paronen I, Mahonen H. Reiter’s syndrome: a follow-up study. Acta Med Scand. 1969;185(1–2):57–63.PubMedGoogle Scholar
  29. 29.
    Noer HR. An “experimental” epidemic of Reiter’s syndrome. JAMA. 1966;198(7):693–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Calin A, Fries JF. An “experimental” epidemic of Reiter’s syndrome revisited. Follow-up evidence on genetic and environmental factors. Ann Intern Med. 1976;84(5):564–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Hannu T, Mattila L, Siitonen A, Leirisalo-Repo M. Reactive arthritis attributable to Shigella infection: a clinical and epidemiological nationwide study. Ann Rheum Dis. 2005;64(4):594–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Ajene AN, Fischer Walker CL, Black RE. Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, Salmonella and Shigella-associated reactive arthritis. J Health Popul Nutr. 2013;31(3):299–307.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Dworkin MS, Shoemaker PC, Goldoft MJ, Kobayashi JM. Reactive arthritis and Reiter’s syndrome following an outbreak of gastroenteritis caused by Salmonella enteritidis. Clin Infect Dis. 2001;33(7):1010–4.CrossRefPubMedGoogle Scholar
  34. 34.
    Locht H, Molbak K, Krogfelt KA. High frequency of reactive joint symptoms after an outbreak of Salmonella enteritidis. J Rheumatol. 2002;29(4):767–71.PubMedGoogle Scholar
  35. 35.
    Tuompo R, Hannu T, Mattila L, Siitonen A, Leirisalo-Repo M. Reactive arthritis following Salmonella infection: a population-based study. Scand J Rheumatol. 2013;42(3):196–202.CrossRefPubMedGoogle Scholar
  36. 36.
    Townes JM, Deodhar AA, Laine ES, Smith K, Krug HE, Barkhuizen A, Thompson ME, Cieslak PR, Sobel J. Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon: a population-based study. Ann Rheum Dis. 2008;67(12):1689–96.CrossRefPubMedGoogle Scholar
  37. 37.
    Ekman P, Kirveskari J, Granfors K. Modification of disease outcome in Salmonella-infected patients by HLA-B27. Arthritis Rheum. 2000;43(7):1527–34.CrossRefPubMedGoogle Scholar
  38. 38.
    Rosner BM, Stark K, Hohle M, Werber D. Risk factors for sporadic Yersinia enterocolitica infections, Germany 2009-2010. Epidemiol Infect. 2012;140(10):1738–47.CrossRefPubMedGoogle Scholar
  39. 39.
    Vasala M, Hallanvuo S, Ruuska P, Suokas R, Siitonen A, Hakala M. High frequency of reactive arthritis in adults after Yersinia pseudotuberculosis O:1 outbreak caused by contaminated grated carrots. Ann Rheum Dis. 2014;73(10):1793–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Hannu T, Mattila L, Nuorti JP, Ruutu P, Mikkola J, Siitonen A, Leirisalo-Repo M. Reactive arthritis after an outbreak of Yersinia pseudotuberculosis serotype O:3 infection. Ann Rheum Dis. 2003;62(9):866–9.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Leirisalo-Repo M, Suoranta H. Ten-year follow-up study of patients with Yersinia arthritis. Arthritis Rheum. 1988;31(4):533–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Rautelin H, Hanninen ML. Campylobacters: the most common bacterial enteropathogens in the Nordic countries. Ann Med. 2000;32(7):440–5.CrossRefPubMedGoogle Scholar
  43. 43.
    Pope JE, Krizova A, Garg AX, Thiessen-Philbrook H, Ouimet JM. Campylobacter reactive arthritis: a systematic review. Semin Arthritis Rheum. 2007;37(1):48–55.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Hannu T, Mattila L, Rautelin H, Pelkonen P, Lahdenne P, Siitonen A, Leirisalo-Repo M. Campylobacter-triggered reactive arthritis: a population-based study. Rheumatology (Oxford). 2002;41(3):312–8.CrossRefGoogle Scholar
  45. 45.
    Locht H, Krogfelt KA. Comparison of rheumatological and gastrointestinal symptoms after infection with Campylobacter jejuni/coli and enterotoxigenic Escherichia coli. Ann Rheum Dis. 2002;61(5):448–52.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Keithlin J, Sargeant J, Thomas MK, Fazil A. Systematic review and meta-analysis of the proportion of Campylobacter cases that develop chronic sequelae. BMC Public Health. 2014;14:1203.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Esan OB, Pearce M, van Hecke O, Roberts N, Collins DR, Violato M, McCarthy N, Perera R, Fanshawe TR. Factors associated with Sequelae of Campylobacter and non-typhoidal Salmonella infections: a systematic review. EBioMedicine. 2017;15:100–11.CrossRefPubMedGoogle Scholar
  48. 48.
    Johanesen PA, Mackin KE, Hutton ML, Awad MM, Larcombe S, Amy JM, Lyras D. Disruption of the gut Microbiome: Clostridium difficile infection and the threat of antibiotic resistance. Genes (Basel). 2015;6(4):1347–60.CrossRefGoogle Scholar
  49. 49.
    Prati C, Bertolini E, Toussirot E, Wendling D. Reactive arthritis due to Clostridium difficile. Joint Bone Spine. 2010;77(2):190–2.CrossRefPubMedGoogle Scholar
  50. 50.
    Cappella M, Pugliese F, Zucchini A, Marchetti F. Clostridium difficile Enterocolitis and reactive arthritis: a case report and review of the literature. Case Rep Pediatr. 2016;2016:1591753.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Granfors K, Jalkanen S, Lindberg AA, Maki-Ikola O, von Essen R, Lahesmaa-Rantala R, Isomaki H, Saario R, Arnold WJ, Toivanen A. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. Lancet. 1990;335(8691):685–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Granfors K, Jalkanen S, von Essen R, Lahesmaa-Rantala R, Isomaki O, Pekkola-Heino K, Merilahti-Palo R, Saario R, Isomaki H, Toivanen A. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. N Engl J Med. 1989;320(4):216–21.CrossRefPubMedGoogle Scholar
  53. 53.
    Gaston JS, Cox C, Granfors K. Clinical and experimental evidence for persistent Yersinia infection in reactive arthritis. Arthritis Rheum. 1999;42(10):2239–42.CrossRefPubMedGoogle Scholar
  54. 54.
    Braun J, Tuszewski M, Ehlers S, Haberle J, Bollow M, Eggens U, Distler A, Sieper J. Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. II. Examination of sacroiliac and knee joint biopsies of patients with spondyloarthropathies and other arthritides. J Rheumatol. 1997;24(6):1101–5.PubMedGoogle Scholar
  55. 55.
    Granfors K, Viljanen M, Tiilikainen A, Toivanen A. Persistence of IgM, IgG, and IgA antibodies to Yersinia in Yersinia arthritis. J Infect Dis. 1980;141(4):424–9.CrossRefPubMedGoogle Scholar
  56. 56.
    de Koning J, Heesemann J, Hoogkamp-Korstanje JA, Festen JJ, Houtman PM, van Oijen PL. Yersinia in intestinal biopsy specimens from patients with seronegative spondyloarthropathy: correlation with specific serum IgA antibodies. J Infect Dis. 1989;159(1):109–12.CrossRefPubMedGoogle Scholar
  57. 57.
    Granfors K, Merilahti-Palo R, Luukkainen R, Mottonen T, Lahesmaa R, Probst P, Marker-Hermann E, Toivanen P. Persistence of Yersinia antigens in peripheral blood cells from patients with Yersinia enterocolitica O:3 infection with or without reactive arthritis. Arthritis Rheum. 1998;41(5):855–62.CrossRefPubMedGoogle Scholar
  58. 58.
    Braun J, Yin Z, Spiller I, Siegert S, Rudwaleit M, Liu L, Radbruch A, Sieper J. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum. 1999;42(10):2039–44.CrossRefPubMedGoogle Scholar
  59. 59.
    Saarinen M, Ekman P, Ikeda M, Virtala M, Gronberg A, Yu DT, Arvilommi H, Granfors K. Invasion of Salmonella into human intestinal epithelial cells is modulated by HLA-B27. Rheumatology (Oxford). 2002;41(6):651–7.CrossRefGoogle Scholar
  60. 60.
    Granfors K. Host-microbe interaction in reactive arthritis: does HLA-B27 have a direct effect? J Rheumatol. 1998;25(9):1659–61.PubMedGoogle Scholar
  61. 61.
    Schumacher HR Jr, Gerard HC, Arayssi TK, Pando JA, Branigan PJ, Saaibi DL, Hudson AP. Lower prevalence of Chlamydia pneumoniae DNA compared with Chlamydia trachomatis DNA in synovial tissue of arthritis patients. Arthritis Rheum. 1999;42(9):1889–93.CrossRefPubMedGoogle Scholar
  62. 62.
    Hay EM, Winfield J, McKendrick MW. Reactive arthritis associated with cryptosporidium enteritis. Br Med J (Clin Res Ed). 1987;295(6592):248.CrossRefGoogle Scholar
  63. 63.
    Borman P, Seckin U, Ozoran K. Beaver fever--a rare cause of reactive arthritis. J Rheumatol. 2001;28(3):683.PubMedGoogle Scholar
  64. 64.
    Renou F, Wartel G, Raffray L, Kuli B, Fayeulle S, Yvin JL. Reactive arthritis due to Escherichia coli urinary tract infection. Rev Med Interne. 2011;32(1):e4–5.CrossRefPubMedGoogle Scholar
  65. 65.
    Valtonen VV, Leirisalo M, Pentikainen PJ, Rasanen T, Seppala I, Larinkari U, Ranki M, Koskimies S, Malkamaki M, Makela PH. Triggering infections in reactive arthritis. Ann Rheum Dis. 1985;44(6):399–405.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Ben Abdelghani K, Fazaa A, Souabni L, Zakraoui L. Reactive arthritis induced by intravesical BCG therapy for bladder cancer. BMJ Case Rep. 2014;2014:bcr2013202741.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Kroot EJ, Hazes JM, Colin EM, Dolhain RJ. Poncet’s disease: reactive arthritis accompanying tuberculosis. Two case reports and a review of the literature. Rheumatology (Oxford). 2007;46(3):484–9.CrossRefGoogle Scholar
  68. 68.
    Barber CE, Kim J, Inman RD, Esdaile JM, James MT. Antibiotics for treatment of reactive arthritis: a systematic review and meta-analysis. J Rheumatol. 2013;40(6):916–28.CrossRefPubMedGoogle Scholar
  69. 69.
    Kvien TK, Gaston JS, Bardin T, Butrimiene I, Dijkmans BA, Leirisalo-Repo M, Solakov P, Altwegg M, Mowinckel P, Plan PA, et al. Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis. 2004;63(9):1113–9.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Carter JD, Espinoza LR, Inman RD, Sneed KB, Ricca LR, Vasey FB, Valeriano J, Stanich JA, Oszust C, Gerard HC, et al. Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum. 2010;62(5):1298–307.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Hoogkamp-Korstanje JA, Moesker H, Bruyn GA. Ciprofloxacin v placebo for treatment of Yersinia enterocolitica triggered reactive arthritis. Ann Rheum Dis. 2000;59(11):914–7.CrossRefPubMedGoogle Scholar
  72. 72.
    Calin A. A placebo controlled, crossover study of azathioprine in Reiter’s syndrome. Ann Rheum Dis. 1986;45(8):653–5.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999;42(11):2325–9.CrossRefPubMedGoogle Scholar
  74. 74.
    Lally EV, Ho G Jr. A review of methotrexate therapy in Reiter syndrome. Semin Arthritis Rheum. 1985;15(2):139–45.CrossRefPubMedGoogle Scholar
  75. 75.
    Brinster A, Guillot X, Prati C, Wendling D. Anti-TNF treatment of reactive arthritis. A monocentric experience. Joint Bone Spine. 2017;84(2):237–8.CrossRefPubMedGoogle Scholar
  76. 76.
    Meyer A, Chatelus E, Wendling D, Berthelot JM, Dernis E, Houvenagel E, Morel J, Richer O, Schaeverbeke T, Gottenberg JE, et al. Safety and efficacy of anti-tumor necrosis factor alpha therapy in ten patients with recent-onset refractory reactive arthritis. Arthritis Rheum. 2011;63(5):1274–80.CrossRefPubMedGoogle Scholar
  77. 77.
    Tanaka T, Kuwahara Y, Shima Y, Hirano T, Kawai M, Ogawa M, Arimitsu J, Hagihara K, Narazaki M, Ogata A, et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum. 2009;61(12):1762–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.INSERM U1132, Rheumatology DepartmentLariboisière Hospital Paris and University Paris DiderotParisFrance

Personalised recommendations